-
"New Cells for ALS Patients: Surgeons have transplanted a second dose of neural cells into a patient’s spinal cord in
a pioneering trial."
MIT’s Technology Review publishes feature story on Neuralstem’s technology’s “pioneering trial” and final ALS Phase I patient Ted Harada’s return treatment. Includes interviews with principal investigator Dr. Feldman and CEO Richard Garr.
Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.